SCHOLARReal-world Impact of Semaglutide Once-weekly on Type 2 Diabetes Patients in China

This study focuses on understanding the real-life use and effects of a once-weekly medication called semaglutide among individuals with type 2 diabetes in China. The study includes people who have been diagnosed with type 2 diabetes and have started using semaglutide for the first time between January 1, 2022, and February 28, 2023. The goal is to gain insights into how this medication is used in everyday clinical practice and how it impacts patients' health. This research is important as it can provide valuable information on the effectiveness and safety of semaglutide in a real-world setting, potentially improving care for those with type 2 diabetes. During the study, participants will continue with their regular healthcare routine while using semaglutide once a week. The study will measure changes in a substance called Haemoglobin A1c (HbA1c), which gives an idea of average blood sugar levels over the past few months. This will be measured in two units: percentage (%), and millimoles per mol (mmol/mol). Additionally, the study will look at the proportion of participants who achieve an HbA1c level of less than 7.0%. These measurements will help evaluate how well semaglutide helps manage blood sugar levels in people with type 2 diabetes.